capital management, page-10

There will be a point within the next year or two when TST sales will reach a point where some of the global manufacturers will consider ceasing production. CSL in Australia have already ceased production and are sourcing from overseas. As sales go down other manufacturers will follow leaving fewer and fewer suppliers. Price will go up as competition decreases and the economic benefits of QFT will emerge.

Give it time and QFT will gain the critical mass of clinical support and become the the gold standard and we will be looking at sales increasing exponentially.